The Role of Sacubitril/Valsartan in Post-acute Myocardial Infarction
Status:
Recruiting
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
Sacubitril/Valsartan (SAC/VAL) is a new treatment of congestive heart failure (CHF) recently
indicated as class I, level of evidence B in the recent European Society of Cardiology (ESC)
guidelines 2016 of CHF. PARADIGM-HF trial demonstrated a significant improvement of morbidity
and mortality with SAC/VAL in comparison to enalapril. So far, no data available about the
effect of usage of SAC/VAL post-acute myocardial infarction (AMI) except in animal
experimental models.
The purpose of the research is evaluation of the effects of SAC/VAL in post-AMI in comparison
to the traditional Angiotensin Converting Enzyme inhibitors (ACEs inhibitors) or Angiotensin
II Receptor Blockers (ARBs) in a real-life clinical trial in treatment of post-AMI patients
with reduced left ventricular (LV) systolic function.
Phase:
N/A
Details
Lead Sponsor:
The Young Investigator Group of Cardiovascular Research
Treatments:
LCZ 696 Sacubitril and valsartan sodium hydrate drug combination Valsartan